INTRODUCTION
The therapeutic success of immunoglobulin G (IgG) antibodies such as rituximab (a chimeric CD20-specific IgG1 antibody) and herceptin (a her2/neu-specific IgG1 antibody) in the treatment of human cancer and autoimmune disease has fueled interest in the widespread development of IgG-based biologicals (Carter, 2006; St Clair, 2009; Waldmann, 2003; Weiner et al., 2010) . Animal model systems frequently used for the preclinical evaluation of IgG activity and safety include mice, rats, and a variety of nonhuman primate species. Because they provide the possibility to delete genes of choice, mouse in vivo model systems are widely used, and many of our current models of IgG activity stem from data obtained in mice. Indeed, such studies have provided valuable insights into the mechanism of IgG activity, such as the importance of cellular Fcg receptors (FcgR) for IgG activity and the role of individual FcgRs in IgG subclass activity in vivo (Beers et al., 2008; Hogarth, 2002; Nimmerjahn and Ravetch, 2008; Takai, 2002) . The relevance of these basic studies to the human system is supported by data showing that cancer patients respond better to anticancer antibodies if they express allelic variants of FcgRs that confer enhanced binding to the IgG subclass of the therapeutic antibody (Cartron et al., 2002; Musolino et al., 2008; Weng et al., 2004; Weng and Levy, 2003) . Despite the similarities between mice and humans, however, there are several important differences, such as the cell-type-specific expression pattern of certain FcgRs and the capacity of some mouse FcgRs to interact with other Ig isotypes, which are not reflected in humans (Hirano et al., 2007; Mancardi et al., 2008; Nimmerjahn et al., 2010; Biburger and Nimmerjahn, 2012) . As mentioned in previous studies, allelic variants of the low-affinity FcgRs FcgRIIB, FcgRIIA, and FcgRIIIA are present in the human population that can impact either the affinity or functionality of these receptors (Baerenwaldt et al., 2011; Bruhns et al., 2009; Smith and Clatworthy, 2010) . Moreover, certain human FcgRs, such as the neutrophil-specific FcgRIIIB, are not present in mice at all. Thus, several factors that potentially influence IgG activity in humans are not recapitulated in any of the currently available animal models, including nonhuman primates. To combine the advantages of a small-animal model with the possibility to study the human immune system in vivo, we used the Rag2/ Il2rg-deficient mouse strain (Rag2/gcÀ/À), in which a functional human immune system can develop upon injection with purified human hematopoietic stem cells (HSCs) due to the absence of mouse B cells, T cells, and functional natural killer (NK) cells (Legrand et al., 2008; Shultz et al., 2012; Traggiai et al., 2004; Legrand et al., 2009) . Although these mice are an excellent model system for studying the development of the human immune system, they may not be the optimal system for studying human IgG activity in vivo. This is due to the presence of mouse monocytes, macrophages, and neutrophils expressing high levels of mouse activating FcgRs, which have the capacity to interact with human IgG1 antibodies . Further complicating the situation, the absence of mouse B cells and mouse serum antibodies will result in a high capacity of the mouse high-affinity FcgRI, which is usually occupied with mouse serum IgG2a, to interact with human IgG1, thereby artificially skewing antibody effector functions toward this receptor.
Thus, we set out to generate an immunodeficient mouse model that would accept human HSC grafts without expressing mouse activating FcgRs. We show that this mouse strain efficiently accepts human HSC grafts, which develop into a human immune system containing all the major hematopoietic cell lineages. By using human CD20-specific monoclonal antibodies, we demonstrate that human IgG subclasses have a differential activity in vivo and depend critically on the IgG constant fragment. Moreover, this model system allowed us to identify physiological niches, such as the bone marrow, in which human IgG activity might be less effective. 
RESULTS
Generation and Characterization of Rag2/gc/FcRgÀ/À Mice Although Rag2/gcÀ/À mice have allowed unique insights into human immune system development and function to be obtained, studying human IgG activity in this and other immunodeficient mouse strains transplanted with human peripheral blood mononuclear cells (PBMCs) are hampered by the fact that many human IgG subclasses, and especially human IgG1, which is the most abundant IgG subclass used in human therapy, can bind to mouse activating FcgRI and FcgRIV . To test whether human IgG1 can indeed mediate its activity via one of these mouse FcgRs in vivo, we generated a humanized IgG1 variant of the mouse platelet-specific antibody 6A6 . Indeed, 6A6-hIgG1 efficiently depleted platelets in C57BL/6 and FcgRIdeficient mice, but was not able to remove platelets in FcRg-deficient mice lacking all activating FcgRs and in FcgRIV-deficient animals, consistent with previous studies that demonstrated an important role for this mouse activating FcgR in IgG activity in vivo (Figures 1A and 1B; Nimmerjahn et al., , 2010 Seeling et al., 2013; Biburger et al., 2011; Mancardi et al., 2011; Otten et al., 2008; Kasperkiewicz et al., 2012; Syed et al., 2009; Baudino et al., 2008; Kaneko et al., 2006; Hamaguchi et al., 2006) . These results emphasize that studying human IgG activity in currently available immunodeficient mouse strains transplanted with human immune cells will not allow us to distinguish between effector functions mediated by mouse and human innate immune effector cells unless we can discover transplantation conditions that completely eradicate all mouse hematopoietic cells. Therefore, to generate an immunodeficient mouse strain that does not express mouse activating FcgRs, we crossed the Rag2/gcÀ/À mouse strain, which is known to efficiently accept human hematopoietic cells, with the FcRg-deficient mouse, thereby creating Rag2/gc/ FcRgÀ/À mice. As shown in Figures 1C and 1D , these animals lack mouse B and T cells, and do not express mouse activating FcgRs on innate immune effector cells, such as neutrophils and monocytes, resulting in abrogated activity of the 6A6-hIgG1 antibody ( Figure 1B) . Thus, upon reconstitution of Rag2/gc/FcRgÀ/À mice with a human immune system, only human innate immune effector cells will express human activating FcgRs, which allowed us to exclude the contribution of residual mouse innate immune effector cells beyond any doubt. Figure S1 and Table S1 .
Reconstitution of a Human
newborn mice with 6 Gy resulted in the highest level of reconstitution with human hematopoietic cells in the peripheral blood of individual mice 12 weeks after transplantation ( Figure S1A ). As previously described for other immunodeficient mouse strains, in addition to the blood, human cells were abundantly present in the spleen and bone marrow of the reconstituted animals ( Figure S1B ; Table S1 ; Shultz et al., 2012; Tanaka et al., 2012; Traggiai et al., 2004) . Moreover, the level of reconstitution did not impact the cell lineages present in these animals, as B cells, T cells, monocytes, and NK cells could be found at comparable levels in mice with a low or high reconstitution level ( Figures S1C and S1D) . A more detailed analysis of human cell types present in the blood, spleen, and bone marrow of transplanted animals identified T cells, monocytes, NK cells, and dendritic cells, as well as B cells in early and late differentiation stages, including pro-(CD34+CD19+CD10+IgMÀ), pre-(CD34ÀCD19+CD10+IgMÀ), immature (IgM+CD19+CD10+), and mature (IgM+CD19+CD10À) B cells (Figures 2A-2C ), in line with previous reports (Blom and Spits, 2006; Ghia et al., 1998; Tanaka et al., 2012; Traggiai et al., 2004) . Consistent with the presence of B cells, serum IgM and IgG were present in the serum of mice, albeit at much lower levels than in human serum ( Figure 2D ). However, this amount seemed sufficient to result in binding to CD33+ myeloid cells, most likely via the (legend continued on next page)
high-affinity FcgRI expressed on this cell type (Figures 2E and 4A) . In contrast to the presence of all essential cell types important for IgG-dependent effector functions, these mice did not produce significant levels of human complement, consistent with the important role of nonhematopoietic tissues, such as the liver, for the generation of complement proteins ( Figure 2F ). Furthermore, CD66c/CD16B+ neutrophils and CD68+ macrophages were abundantly present in the spleen of humanized mice, as demonstrated previously in other humanized immunodeficient mouse strains ( Figure 3A ; Tanaka et al., 2012) . Since others have demonstrated that these human macrophages are functional with respect to cytokine secretion and phagocytic function (Tanaka et al., 2012) , we turned our attention to another bone resident macrophage population, namely, osteoclasts, which had not previously been investigated in humanized mice. First, we cultured bone marrow of humanized mice and human PBMCs with macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kB ligand (RANKL), which drives monocyte precursors into the osteoclast lineage (Nakashima et al., 2012) . As shown in Figure 3B , this indeed resulted in the generation of mature osteoclasts, identified by large multinucleated cells expressing the osteoclast marker tartrateresistant acid phosphatase (TRAP). More importantly, these osteoclasts were fully functional, as demonstrated by their capacity to resorb bone matrix ( Figure 3C ). In contrast to the presence of human macrophages in the spleen, no CD68-expressing cells were detectable in the bone marrow and blood of the humanized mice and humans ( Figure 3D ). A prerequisite for studying human IgG-dependent effector functions in humanized mice is the presence of human FcgRs on innate immune effector cells. In humans, FcgRIIIA is the only activating FcgR expressed on NK cells, whereas monocytes and macrophages express a broader repertoire of activating FcgRs (Hogarth, 2002; Ravetch and Nimmerjahn, 2008) . As shown in Figure 4A , NK cells expressing FcgRIIIA and monocytes positive for FcgRIA, FcgRIIA, FcgRIIB, and FcgRIIIA were present in the blood, spleen, and bone marrow of these animals. In combination with FcgRIIIB expression on human neutrophils ( Figure 3A ), this suggests that all relevant human FcgRs are expressed on innate immune effector cells. This cell-type-specific pattern of FcgR expression was consistent with the presence of these receptors on CD33+ monocytes in the respective human organs ( Figure 4B ), suggesting that human FcgR expression is fully recapitulated in the humanized Rag2/ gc/FcRgÀ/À mice. In a notable exception, there was a low level of FcgRIIB expression on monocytes in the peripheral blood of humanized mice, whereas their counterparts in the human blood were mostly negative for this receptor.
Activity of Human CD20-Specific IgG Subclasses in Humanized Mice
Because CD20 is the major target for therapeutic B celldepleting antibodies, we next assessed the CD20 expression pattern on human B cells developing in humanized mice and humans (Johnson and Press, 2000; Sanz and Lee, 2010) . As shown in Figure 5A , CD20 was highly expressed on all IgM+ B cell populations in the blood, spleen, and bone marrow of humanized mice. In contrast, pro-and pre-B cell populations expressed only very small amounts of CD20, whereas the majority of immature B cells were strongly positive for this marker. Of note, mouse CD20 has been demonstrated to be absent from pro-B and the vast majority of pre-B cells, and to be expressed only starting from the very late pre-B to immature B cell stage. Interestingly, this mouse-specific expression pattern was recapitulated in transgenic mice expressing human CD20, further emphasizing the need for humanized mouse models to fully match the human expression pattern especially during early B cell development (Gong et al., 2005; Uchida et al., 2004b) .
As a CD20-specific therapeutic antibody, we chose the hybridoma clone 1F5, which was used in early human clinical trials to deplete B cells in its mouse IgG2a form, and generated all four human IgG subclass switch variants of this antibody (Johnson and Press, 2000) . Upon injection of equal amounts of these IgG switch variants into humanized mice (10 mg per mouse), we could show that the 1F5-IgG1, 1F5-IgG2, and 1F5-IgG3 variants were more efficient in reducing B cell counts compared with 1F5-IgG4 ( Figures 5B-5D ). Importantly, this different level of activity could not be explained by a different half-life of these IgG switch variants in humanized mice in vivo ( Figure S2A ). In a similar manner, the amount of human cells present in these animals did not correlate with the level of B cell depletion ( Figures  S2B-S2D ). Of note, although human IgG4 is widely considered not to have any cytotoxic activity, it clearly had the capacity to deplete B cells, which is consistent with recent in vitro studies demonstrating that especially large IgG4 immune complexes can indeed bind to FcgRs, such as FcgRI (Bruhns et al., 2009; Lux and Nimmerjahn, 2011) . Overall, the observed differences in in vivo activity are in line with previous results obtained in classical mouse models, which demonstrated that the activity of IgG subclasses in vivo correlates with their affinity for different FcgRs (Fossati-Jimack et al., 2000; Hamaguchi et al., 2006; . With respect to the kinetics of B cell depletion, the majority of B cells were absent from the peripheral blood of humanized mice 24 hr after anti-CD20 injection (Figure 5C ). Especially for the IgG1 and IgG2 switch variants, B cell depletion was long lasting and B cell counts did not return to normal levels over the observation period of the experiment ( Figure 5D ). Similar results have been obtained in murine models of B cell depletion with CD20-specific antibodies and in human patient cohorts treated with rituximab ( Figure S2E ; Hamaguchi et al., 2006; Sanz et al., 2007; Uchida et al., 2004a; Beers et al., 2008) . Of note, B cell depletion was fully dependent on the IgG Fc fragment, as neither F(ab 0 ) 2 fragments nor deglycosylated variants of the same antibody were able to induce a reduction in B cell counts ( Figures 5E and 5F ). These findings support the notion that despite the capacity of antibodies against CD20 (C) Assessment of the capacity of osteoclasts generated from the bone marrow of humanized mice in the presence of M-CSF and the indicated concentrations of RANKL to resorb bone matrix. (D) Analysis of humanized mouse or human blood and bone marrow to detect CD68+ macrophages. All experiments were done with animals at 12-16 weeks posttransplantation with human HSCs and at least two animals per group. Bar graphs indicate mean value ± SD.
to directly inhibit B cell proliferation and induce apoptosis without secondary crosslinking in vitro, the IgG Fc fragment is crucial for anti-CD20-dependent B cell depletion in vivo (Bonavida, 2007; Shan et al., 1998) .
To determine whether FcgR allelic variants represented in the HSCs used to reconstitute the mice with a human immune system might explain some of the differences in antibody activity observed between the higher-and lower-responder mice, we genotyped the donors (Table S2) and color-coded all of the mice that carried specific FcgRIIA high/low affinity and FcgRIIIA high/low affinity alleles. As shown in Figures 5C and 5D , this did not show a clear correlation with the activity of antibody-mediated B cell depletion. Similar results were obtained in human lymphoma patients before and after treatment with rituximab, suggesting that B cell depletion is not affected by differences in FcgR allelic variants, at least at the studied antibody 
. Expression of Human FcgRs on Innate Immune Effector Cells
Expression of the indicated human FcgRs on CD33+ monocytes and CD56+ NK cells in the blood, spleen, and bone marrow of humanized Rag2/gc/FcRgÀ/À mice (A) or humans (B) as determined by flow cytometry. Depicted is a representative result from nine independent animals at 12-16 weeks posttransplantation or a minimum of three independent human samples. Cells from five humanized mice were pooled for staining of FcgR expression on peripheral blood cells.
concentration in the blood of humanized mice and humans (Figure S2E) . In addition to the blood, we also investigated the capacity of the IgG1 switch variant to deplete B cells in the spleen and bone marrow. As shown in Figures 6A-6C , a single injection of 1, 10, and 100 mg anti-CD20 IgG1 efficiently depleted mature B cells in the blood and spleen. In contrast, depletion of mature B cells in the bone marrow was less efficient and required an at least 10-fold higher antibody dose ( Figure 6D ). Even more striking, although the immature B cells expressed CD20 to a level comparable to that observed in mature B cells, they never reached a significant level of depletion. The same applied for pro-and pre-B cells, although these B cell subsets clearly expressed much lower amounts of this cell-surface marker ( Figures  5A and 6D) . Again, no clear correlation with the allelic variants of activating FcgRs was notable (Table S3) . A possible explanation for this phenomenon might be a lower availability of the therapeutic CD20-specific antibody in the bone marrow. To address this question experimentally, we injected a fluorescently labeled aglycosylated version of the CD20-specific antibody to prevent the rapid depletion of anti-CD20-coated B cells in the blood and spleen. As shown in Figures 6E and 6F , all mature B cell populations were labeled by the injected antibody regardless of their anatomical localization. In line with the comparable level of CD20 expression, immature B cells displayed the same amount of therapeutic antibody binding as mature B cells. As expected, proand pre-B cells were stained at a lower but still clearly detectable level. Another reason for this reduced level of B cell depletion may be the lack of responsible innate immune effector cells. As shown in Figures 2A and 4A , however, NK cells and CD33+ myeloid cells were present in the bone marrow. A more detailed analysis of the CD33+ cells in the bone marrow revealed that the majority of these were negative for c-kit and CD34, and thus represent more mature CD14 high-and low-monocyte subsets, as expected ( Figure 6G ). In contrast to monocytes, CD68+ macrophages were present only in very low amounts in the bone marrow or virtually absent in the blood from humanized mice and humans ( Figure 3D ). To further validate this observation, we analyzed the efficacy of B cell depletion in the bone marrow of C57BL/6 mice with an antibody specific for mouse CD20. Again, the depletion of immature B cells required a much higher dose, despite a similar binding of the CD20-specific antibody compared with mature B cells, which were depleted with a similar efficacy compared with the blood and spleen ( Figure S3 ), in line with previous reports. In contrast to what was observed in humans and humanized mice, pro-B and pre-B cells in C57BL/6 mice did not express CD20, and accordingly could not be recognized via the CD20-specific antibody ( Figure S3B ). Therefore, it was not possible to assess their depletion, providing yet another argument for the necessity of a humanized mouse model.
DISCUSSION
Taken together, our results provide evidence that Rag2/gc/ FcRgÀ/À mice might be a valuable tool for studying human IgG activity in a preclinical setting in vivo. Compared with injecting human PBMCs into immunodeficient Rag2/gcÀ/À, NOD/ SCID, or NOD/SCID/gcÀ/À mice, which are frequently used as surrogate humanized mouse models to study human IgG activity, this mouse model has several advantages (Goldman et al., 1998; Ito et al., 2002) . Most importantly, mouse innate immune effector cells in Rag2/gc/FcRgÀ/À mice no longer have functional activating FcgRs, which allowed us to study the interaction of human antibodies with human target and effector cells in vivo. Our work reveals that human IgG4 antibodies are able to deplete target cells, and is fully consistent with recent in vitro studies (Bruhns et al., 2009; . Moreover, the presence of B cells in all developmental stages expressing physiological levels of the target antigen in all relevant organ structures and niches is not reflected in the NOD/SCID model system reconstituted with human PBMCs in the peritoneum. Similar arguments apply to transgenic mouse models that express human B cell antigens, such as human CD19 and CD20, on mouse B cells (but lack human innate immune effector cells), and to mice that are transgenic for all human FcgRs, in which human serum antibodies and the target human antigen are not present (Beers et al., 2008; Gong et al., 2005; Yazawa et al., 2005; Smith et al., 2012) . Of note, the expression pattern of human CD20 on early mouse B cell progenitors in the bone marrow of human CD20 transgenic mice seems to mimic the expression pattern of mouse CD20, being virtually absent from pro-B and pre-B cell stages (Gong et al., 2005; Uchida et al., 2004b) . In contrast, the expression of human CD20 in humanized Rag2/gc/FcRgÀ/À mice fully resembled the human expression pattern. Another attractive feature is the long-term reconstitution with human immune cells, which may allow the activity of therapeutic antibodies to be monitored over a longer observation period compared with the transient availability of human cell subsets in PBMC-reconstituted animals. Despite these advantages, however, there are also obvious disadvantages, including the variability in reconstitution and the genetic heterogeneity among donors. This may require larger groups of animals to obtain conclusive results, but in the end might mimic the human situation more closely. The other point to be considered is that the human immune system in humanized mice represents a 4-to 6-month-old developmental stage and thus may not fully be comparable to the immune system of an adult human. This may explain at least in part some of the differences we observed with respect to the level of FcgR expression and the overrepresentation of certain cell types, primarily B cells, especially early after reconstitution.
By studying antibody-dependent B cell depletion in this model system, we were able to show that the efficacy of target cell depletion varied greatly depending on the anatomical site. Thus, whereas mature B cells of the peripheral blood and the spleen were depleted very effectively even by small antibody doses, an at least 10-fold higher amount of antibody was required to deplete mature B cells in the bone marrow. Although immature B cells expressed only slightly lower levels of CD20 compared with mature B cells and were bound by the same amount of cytotoxic antibody, they did not become depleted efficiently even at high antibody doses, suggesting that the bone marrow may represent a niche with low antibody-dependent cell-mediated cytotoxicity (ADCC) activity. An alternative but nonmutually exclusive explanation is that immature B cells are somehow resistant to antibody-mediated depletion. A similar but less pronounced effect could be observed in a model system Cell Reports 7, 1-13, April 10, 2014 ª2014 The Authors 7 of anti-CD20-mediated depletion of mouse B cells, in which a 5-fold higher dose was required to deplete immature B cells effectively, consistent with earlier results . Further along these lines, immature mouse B cells expressing human CD20 as a transgene showed a similar resistance to anti-CD20-dependent depletion (Gong et al., 2005) . The higher ADCC activity toward mature mouse B cells may be explained at least in part by the much higher affinity of the mouse IgG2a antibody subclass for the respective murine activating FcgRI and FcgRIV, which are responsible for B cell depletion in the mouse (Biburger et al., 2011; Hamaguchi et al., 2006; Beers et al., 2010) . With respect to earlier B cell subsets, which were also bound by the CD20 antibody, their much lower expression of CD20 may explain at least in part their resistance to depletion. As this was not the case for immature B cells, however, other explanations have to be considered. Apart from antibody availability, a lack of effector cells required for B cell killing may have the same effect on ADCC efficacy. CD16+ NK cells, however, were abundantly present in the bone marrow. Moreover, CD33/ CD16+ monocytes negative for the early monocyte precursor markers CD34 and CD117 were present in the bone marrow and have the capacity to develop into fully functional human macrophages (Tanaka et al., 2012; Li et al., 2013) . It remains possible, however, that although monocytes express all relevant activating FcgRs and are involved in ADCC reactions in the blood, they may not be involved in ADCC reactions in the bone marrow. Alternatively, macrophages have been implicated as ADCC effector cells in other tissues, such as the liver (Montalvao et al., 2013; van der Bij et al., 2010) . In the bone marrow of humanized mice and humans, only very few CD68+ cells could be detected, which may provide an alternative explanation for the lower ADCC activity. Since a small level of cell depletion could be achieved at high antibody doses, it will be interesting to investigate the capacity of ADCC-enhanced antibodies (e.g., lacking branching fucose residues) to efficiently deplete B cells in the bone marrow.
Thus far, we have not observed a correlation between the efficacy of B cell depletion in the peripheral blood and spleen of humanized mice or humans and the presence of high-or low-affinity FcgRIIA and IIIA alleles, which have been correlated with a better therapeutic outcome for lymphoma or breast cancer patients undergoing antibody therapy (Cartron et al., 2002; Musolino et al., 2008; Weng et al., 2004; Weng and Levy, 2003) . To obtain more informative results, we may need to focus on larger humanized mouse colonies that exclusively carry either the high-or low-affinity allelic variants of FcgRIIIA and FcgRIIA, respectively, and study B cell depletion especially in the bone marrow. Altogether, this humanized mouse model should allow a more detailed understanding of human IgG activity on the background of a human immune system, and may become a valuable preclinical test system to validate IgG-based immunologicals. Given the capacity of human myeloid precursor cells to develop into human osteoclasts, this mouse model may also be suitable for investigating autoantibody-mediated bone loss in human serum transfer arthritis models.
EXPERIMENTAL PROCEDURES
Mice C57BL/6 mice were bought from Janvier, and Balb/c-Rag2/gcÀ/À (Rag2/ gcÀ/À) mice were provided by Hergen Spits (AMC Amsterdam). FcgRI-deficient mice (FcgRIÀ/À) and FcgRIV-deficient mice (FcgRIVÀ/À) on the C57BL/6 background, as well as fcer1g-deficient mice (FcRgÀ/À) on the Balb/c and C57BL/6 backgrounds, were provided by Jeffrey Ravetch (Rockefeller University) and Mark Hogarth (Burnet Institute). Balb/c-Rag2/ gc/FcRgÀ/À (Rag2/gc/FcRgÀ/À) mice were generated by crossing Balb/ c-Rag2/gcÀ/À with Balb/c-FcRgÀ/À animals followed by breeding to a homozygous deletion for all three respective genes. Mice were kept in the animal facilities of Friedrich-Alexander-University Erlangen-Nü rnberg and Rockefeller University under specific pathogen-free conditions in individually ventilated cages according to the guidelines of the National Institutes of Health and the legal requirements of Germany and the United States. Immunodeficient Rag2/gcÀ/À and Rag2/gc/FcRgÀ/À mice were supplied with acidified drinking water (pH 3.0) to minimize the risk of bacterial infections in these heavily immunocompromised mouse strains.
Generation of Humanized Mice
Newborn Rag2/gc/FcRgÀ/À mice were irradiated at the indicated doses and injected intravenously with 50,000-80,000 human HSCs 4-6 hr after irradiation. HSCs were purified from umbilical cord blood with the written consent of patients and according to the ethical guidelines of the University of Erlangen-Nü rnberg and the Klinikum Fü rth. In brief, PBMCs were isolated by density centrifugation and CD34+ HSCs were purified using the Direct CD34 Progenitor Cell Isolation Kit, human (Miltenyi Biotec) according to the manufacturer's instructions. Isolated HSCs were frozen and stored in liquid nitrogen until further use.
In Vivo Platelet Depletion Assay
The ability of murine activating FcgR to mediate human IgG effector functions was analyzed by intravenous injection of 10 mg of a humanized anti-platelet (clone 6A6-hIgG1) in C57BL/6, FcRgÀ/À, FcgRIÀ/À, and FcgRIVÀ/À mice (all on the C57BL/6 background), and in Rag2/gcÀ/À and Rag2/gc/FcRgÀ/À mice. As described previously, platelet counts in the peripheral blood of individual mice were assessed before and 4 hr after 6A6-hIgG1 injection with the use of an Advia120 Hematology System (Siemens) .
Fluorescence-Activated Cell Sorting Analysis
Fluorescence-activated cell sorting (FACS) analysis was conducted with PBMCs isolated from the peripheral blood of humanized mice and human cancer patients, with their written consent and according to the ethical guidelines of the University of Erlangen-Nü rnberg, by Ficoll density gradient centrifugation. For bone marrow and spleen, we prepared single-cell suspensions before proceeding to FACS analysis. The following antibodies were used for staining of murine PBMCs and FcgRs in C57BL/6, Rag2/gcÀ/À, and Rag2/gc/FcgÀ/À mice: APC-conjugated B220 (clone RA3-6B6) (HR-FF, RR-FF, and RR-FV) are depicted in red, medium-affinity donors (HR-FV) are shown in black, and high-affinity donors (HR-VV, HH-FV, and HH-VV) are shown in green. (E) Groups of humanized mice were injected with intact anti-CD20 IgG1 or an anti-CD20 F(ab) 2 fragment, and B cell counts were assessed 1 day after antibody injection. (F) Peripheral blood B cell counts in humanized mice 24 hr after injection of PBS, intact 1F5, or aglycosylated 1F5 antibody (PNGaseF). Statistical analysis was performed by Kruskal-Wallis test and subsequent post hoc tests. Asterisks indicate values with a significant difference. *p < 0.05, **p < 0.01. See also Figure S2 and Table S2 . PerCP-conjugated B220 (clone RA3-6B6), fluorescein isothiocyanate (FITC)-conjugated TCRb (clone H57-597), PerCP-Cy5.5-conjugated CD11b (clone M1/70), PE-conjugated CD16/CD32 (clone 2.4G2), biotin-conjugated CD45.2 (clone 104), CD64 (clone X54-517.1), PE-Cy7-conjugated CD62L (clone MEL-14), FITC-conjugated IgD (clone 11-26c.2a), APC-conjugated GR-1 (clone RB6-8C5), FITC-conjugated Ly6G (clone 1A8), biotinylated IgM (clone II/41), and PE-conjugated CD43 (clone Ly-48) (all purchased from BD Pharmingen). APC-H7-conjugated CD45 (clone 30-F11) was purchased from BioLegend. PE-conjugated CD16 (clone 275003) was purchased from R&D. PE-conjugated Nkp46 (clone 29A1.4) and PE-7-conjugated CD19 (clone 1D3) were purchased from eBioscience. The following antibodies (purchased from BD Pharmingen) were used for staining of human cells and FcR in humanized Rag2/gc/FcgÀ/À mice: PerCP-conjugated CD3 (clone UCHT1), FITC-conjugated CD10 (clone HI10a), PerCP-conjugated CD14 (clone M5E2), FITC-conjugated CD16 (clone 3G8), PE-conjugated CD16 (clone 3G8), PE-conjugated CD16B (clone CLB-gran11.5), PE-conjugated CD19 (clone HIB19), PE-Cy7-conjugated CD19 (clone SJ25C1), PE-Cy7-conjugated CD33 (clone P67-6), PE-conjugated CD34 (clone 8.G12), PerCP-conjugated CD45 (clone 2D1), APC-conjugated CD45 (clone HI30), APC-H7-conjugated CD45 (clone 2D1), PE-conjugated CD56 (clone NCAM16.2), FITC-conjugated CD64 (clone 10.1), purified CD66c (clone B6.2/CD66), PE-conjugated CD68 (clone Y1/82A) PE-conjugated CD117 (clone 104D2), biotinylated IgD (clone IA6-2), biotinylated IgM (clone G20-127), and PE-conjugated IgM (clone G20-127). FITC-conjugated CD11c (clone 3.9) was purchased from eBioscience. Alexa647-conjugated CD32 (clone FUN-2) and PerCP-conjugated CD56 (clone HCD56) were purchased from BioLegend. PE-conjugated human IgG was purchased from Jackson ImmunoResearch. APC-Cy7-conjugated streptavidin for detection of biotinylated primary antibodies was purchased from BD Pharmingen. The following antibodies were produced in our laboratory: murine Alexa647-conjugated FcgRIV (clone 9E9), human biotinylated CD32B (clone 2B6), human FITC-conjugated CD20 (clone 1F5), and human A647-conjugated CD20 (clone 1F5). FACS staining was generally conducted in the presence of unlabeled CD16/CD32 antibody (clone 2.4G2; Serotec) as a murine Fc blocking reagent, except for direct analysis of murine FcgRs. To increase the cell number of rare cell populations, such as NK cells, in the peripheral blood of humanized mice, blood from several animals was pooled. Experiments were acquired on a FACSCantoII (BD) and analyzed using FACSDiva or FlowJo software.
Cloning and Production of Antibodies
Human anti-CD20 IgG (clone 1F5) switch variants were generated as previously described . In brief, total RNA was isolated from the 1F5 hybridoma cell line (obtained from ATCC) and subjected to 5 0 -RACE using the 5 0 RACE System for Rapid Amplification of cDNA ends (Invitrogen) according to the manufacturer's instructions. The sequences of the specific primers were as follows: 5 0 -gac agg gat cca gag tt-3 0 (IgG2a heavy-chain gene-specific primer 1), 5 0 -gta ctc tag agg tca agg tca ctg gct ca-3 0 (IgG2a heavy-chain gene-specific primer 2), 5 0 -cct gtt gaa gct ctt gac a-3 0 (k light-chain gene-specific primer 1), and 5 0 -gta ctc tag agg gtg aag ttg atg tct tgt c-3 0 (k light-chain gene-specific primer 2). The light-and heavy-chain variable regions were cloned in pCR-Topo-Blunt (Invitrogen) and confirmed by sequencing. Primers for PCR amplification of variable regions and subsequent cloning were derived from the resulting sequence information: 5 0 -cgt aga att cac cac cat ggg atg gag ttg tat cat c-3 0 (1F5 VH) and 5 0 -cgt aga att cac cac cat gga ttt tca agt gca gat tt-3 0 (1F5 VL). The heavy-chain variable region was fused to heavy-chain constant regions of the human IgG subclasses and cloned into the eukaryotic pBos expression vector via EcoRI and KpnI restriction sites. The kappa light-chain variable region was fused to the human kappa light-chain constant region and cloned in the pCMV vector via NcoI and XhoI restriction sites. Antibodies were produced by transient transfection in HEK293T cells and subsequent isolation from the cell culture supernatant by ammonium sulfate precipitation and protein G purification as previously described . The integrity of the produced switch variants was confirmed by reducing PAGE. The F(ab) 2 fragment of the antibody was generated by digestion with pepsin for 2 hr at 37 C in a buffer of 0.1 M sodium citrate (pH 3.5) followed by dialysis against PBS. Deglycosylation of anti-CD20 IgG was achieved by digestion with 50 U/mg PNGase F overnight at 37 C.
Anti-CD20 IgG-Induced B Cell Depletion In Vivo Anti-CD20 IgG switch variants were intravenously injected into 12-to 16-week-old humanized Rag2/gc/FcRgÀ/À mice at the indicated amounts. B cell counts in peripheral blood were analyzed by flow cytometry before and 1 and 7 days after antibody injection. B cell counts in spleen and bone marrow were analyzed 1 day after antibody application.
ELISA-Based Assays
Serum of humanized Rag2/gc/FcRgÀ/À mice was analyzed for the presence of human C3 protein by a sandwich ELISA using goat human antibody complement C3 F(ab) 2 fragment (Cappel) as the capture antibody and peroxidase-conjugated goat IgG fraction to human complement C3 (Cappel) as the detection antibody. For comparison, human serum and C57BL/6 serum were used as positive and negative controls, respectively. For quantification of total serum IgM and IgG in humanized mice, the Bethyl Human IgM ELISA Quantitation Kit and the Human IgG ELISA Quantitation Kit (Biomol) were used according to the manufacturer's instructions. Optical density was measured with a VersaMax tunable microplate reader (Molecular Devices) at 450 and 650 nm.
Isolation of Genomic DNA and Genotyping
Human FcgRIIA-131H/R and FcgRIIIA-158F/V polymorphisms were determined as previously described (Baerenwaldt et al., 2011) . In brief, 250 ml of umbilical cord blood samples was taken and stored at À20 C before HSCs were isolated. Genomic DNA was isolated with the QiaAmp DSP Blood Mini Kit (QIAGEN) following the instructions of the distributor. To identify the FcgRIIA-131H/R and FcgRIIIA-158F/V allelic variants, allele-specific nested PCRs were performed as previously described (Baerenwaldt et al., 2011) . See also Figure S3 and Table S3 .
Cell Reports 7, 1-13, April 10, 2014 ª2014 The Authors 11
Osteoclast Differentiation Total single-cell bone marrow preparations of humanized Rag2/gc/FcRgÀ/À mice or human peripheral blood (after red blood cell lysis) were cultured overnight with 30 ng/ml of human M-CSF. For osteoclast differentiation, the nonadherent cells were cultured further in a-MEM supplemented with 10% heat-inactivated fetal calf serum, glutamine, penicillin, and streptomycin (all from Invitrogen); 30 ng/ml human M-CSF; and 50 ng/ml hRANKL (PeproTech). After 14 days of culture, the cells were stained for TRAP by using Leukocyte Acid Phosphatase Kit 386A (Sigma-Aldrich) to identify osteoclasts. To determine osteoclast activity, the OsteoLyse Assay Kit (Lonza) was used according to the manufacturer's instructions. In brief, 100,000 nonadherent cells were seeded and after 7 days under osteoclast differentiation conditions, the supernatant was collected. The released fluorescence in the medium was measured using a time-resolved fluorescence fluorimeter (Wallac Victor3; PerkinElmer).
Statistics
The statistical significance of the data was determined as indicated in the figure legends. In brief, the Mann-Whitney test or Wilcoxon signed rank test was applied to compare two experimental groups, and the Kruskal-Wallis test or ANOVA (and subsequent post hoc tests or Mann-Whitney test and Bonferroni correction) were used to determine statistical differences between more than two groups. To indicate different levels of significance, a p value of 0.05 was assigned one asterisk, and a value smaller than 0.05 but larger than 0.001 was assigned two asterisks. Asterics indicate values with a significant difference. **p<0.01. 
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